Combination treatments with hydroxychloroquine and azithromycin are compatible with the therapeutic induction of anticancer immune responses.
Animals
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Azithromycin
/ administration & dosage
COVID-19
/ immunology
Cell Line, Tumor
Cisplatin
/ administration & dosage
Clinical Trials, Phase II as Topic
Crizotinib
/ administration & dosage
Disease Models, Animal
Drug Evaluation, Preclinical
Drug Interactions
Drug Therapy, Combination
/ methods
Female
France
Humans
Hydroxychloroquine
/ administration & dosage
Mice
Neoplasms
/ drug therapy
Oxaliplatin
/ administration & dosage
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
SARS-CoV-2
/ immunology
COVID-19 Drug Treatment
COVID-19
SARS-CoV-2
cancer
hydroxychloroquine
immune checkpoint
immunotherapy
Journal
Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
08 07 2020
08 07 2020
Historique:
entrez:
14
9
2020
pubmed:
15
9
2020
medline:
15
9
2020
Statut:
epublish
Résumé
Amid controversial reports that COVID-19 can be treated with a combination of the antimalarial drug hydroxychloroquine (HCQ) and the antibiotic azithromycin (AZI), a clinical trial (ONCOCOVID, NCT04341207) was launched at Gustave Roussy Cancer Campus to investigate the utility of this combination therapy in cancer patients. In this preclinical study, we investigated whether the combination of HCQ+AZI would be compatible with the therapeutic induction of anticancer immune responses. For this, we used doses of HCQ and AZI that affect whole-body physiology (as indicated by a partial blockade in cardiac and hepatic autophagic flux for HCQ and a reduction in body weight for AZI), showing that their combined administration did not interfere with tumor growth control induced by the immunogenic cell death inducer oxaliplatin. Moreover, the HCQ+AZI combination did not affect the capacity of a curative regimen (cisplatin + crizotinib + PD-1 blockade) to eradicate established orthotopic lung cancers in mice. In conclusion, it appears that HCQ+AZI does not interfere with the therapeutic induction of therapeutic anticancer immune responses.
Identifiants
pubmed: 32923151
doi: 10.1080/2162402X.2020.1789284
pii: 1789284
pmc: PMC7458592
doi:
Substances chimiques
Pdcd1 protein, mouse
0
Programmed Cell Death 1 Receptor
0
Oxaliplatin
04ZR38536J
Hydroxychloroquine
4QWG6N8QKH
Crizotinib
53AH36668S
Azithromycin
83905-01-5
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
1789284Informations de copyright
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.
Références
BMJ. 2020 May 14;369:m1849
pubmed: 32409561
Oncoimmunology. 2018 Aug 1;7(9):e1462431
pubmed: 30228932
BMJ. 2020 May 14;369:m1844
pubmed: 32409486
Oncogene. 2003 Jun 19;22(25):3927-36
pubmed: 12813466
Oncogene. 2010 Jan 28;29(4):482-91
pubmed: 19881547
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32221018
Cell Stress. 2020 Mar 02;4(4):66-75
pubmed: 32292881
Eur Urol. 2020 Aug;78(2):195-206
pubmed: 32376136
Br J Clin Pharmacol. 1989 Jun;27(6):771-9
pubmed: 2757893
Nat Commun. 2019 Apr 2;10(1):1486
pubmed: 30940805
Arthritis Res Ther. 2012 Jun 27;14(3):R155
pubmed: 22734582
Science. 2015 Nov 20;350(6263):972-8
pubmed: 26516201
Cancer Discov. 2014 Aug;4(8):914-27
pubmed: 24875857
Mol Cell. 2010 Oct 22;40(2):280-93
pubmed: 20965422
Cell Death Differ. 2014 Jan;21(1):79-91
pubmed: 23852373
Clin Cancer Res. 2011 Feb 15;17(4):654-66
pubmed: 21325294
Oncogene. 2011 Mar 10;30(10):1147-58
pubmed: 21151176
Nat Rev Clin Oncol. 2016 Jul;13(7):431-46
pubmed: 27030078
Clin Infect Dis. 2020 Jul 28;71(15):732-739
pubmed: 32150618
Science. 2018 Mar 23;359(6382):1366-1370
pubmed: 29567708
Nat Commun. 2020 Jan 16;11(1):307
pubmed: 31949142
Oncoimmunology. 2019 Feb 18;8(4):e1568812
pubmed: 30906663
mBio. 2020 May 22;11(3):
pubmed: 32444382
Travel Med Infect Dis. 2020 Mar - Apr;34:101663
pubmed: 32289548
Ecancermedicalscience. 2017 Nov 23;11:781
pubmed: 29225688
J Am Heart Assoc. 2020 Jun 16;9(12):e017144
pubmed: 32463348
Clin Cancer Res. 2012 Oct 1;18(19):5278-89
pubmed: 22879389
Nat Rev Immunol. 2015 Jul;15(7):405-14
pubmed: 26027717
Oncoimmunology. 2019 Sep 7;8(11):e1657375
pubmed: 31646107
Clin Transl Oncol. 2020 Dec;22(12):2364-2368
pubmed: 32449128
Nat Med. 2020 May;26(5):665-671
pubmed: 32405058
Science. 2018 Jan 5;359(6371):104-108
pubmed: 29302014
Microb Cell. 2020 May 04;7(5):119-128
pubmed: 32391393
Mol Cell Biol. 2005 Feb;25(3):1025-40
pubmed: 15657430
Cell Res. 2019 Oct;29(10):846-861
pubmed: 31481761
Cancer Cell. 2015 Dec 14;28(6):690-714
pubmed: 26678337
Nat Rev Mol Cell Biol. 2020 Feb;21(2):85-100
pubmed: 31636403
Cell Cycle. 2009 Mar 15;8(6):860-9
pubmed: 19221507
Oncoimmunology. 2019 Apr 13;8(7):1596652
pubmed: 31143519
Science. 2018 Jan 5;359(6371):91-97
pubmed: 29097494
Nat Rev Clin Oncol. 2011 May 17;8(9):528-39
pubmed: 21587219
Science. 2013 Nov 22;342(6161):967-70
pubmed: 24264989
Cancer Res. 2007 Oct 15;67(20):10047-57
pubmed: 17942939
J Clin Invest. 2008 Jun;118(6):1991-2001
pubmed: 18523649